| Literature DB >> 34863154 |
Aiai Ma1,2, Kan Jiang3, Bin Chen3, Shasha Chen4, Xinge Qi1, Huining Lu5, Junlin Liu5, Xuan Zhou1,2, Tan Gao1,2, Jinhui Li1, Changming Zhao6,7.
Abstract
BACKGROUND: Endophytic actinomycetes, as emerging sources of bioactive metabolites, have been paid great attention over the years. Recent reports demonstrated that endophytic streptomycetes could yield compounds with potent anticancer properties that may be developed as chemotherapeutic drugs.Entities:
Keywords: Anthraquinones; Anticancer activity; Bioactive metabolites; Cell apoptosis; Cell cycle; Endophytic Streptomyces sp. LRE541; Indole diketopiperazine alkaloid
Mesh:
Substances:
Year: 2021 PMID: 34863154 PMCID: PMC8643024 DOI: 10.1186/s12934-021-01706-z
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Antimicrobial activities of isolate LRE541 against various pathogenic microorganisms
| Test microorganisms | Inhibition zone (mm diameter) |
|---|---|
| Gram-positive bacteria | |
| | 16.67 ± 2.31 |
| | 16 ± 2.65 |
| | 12.33 ± 0.58 |
| | 21.33 ± 1.53 |
| Gram-negative bacteria | |
| | 12.33 ± 1.53 |
| | 12 ± 1.00 |
| The yeast-like fungus | |
| | 7.67 ± 0.78 |
Cultural characteristics of Streptomyces sp. LRE541 on various media
| Media | Growth | Color of colony mycelia | Diffusible pigment | |
|---|---|---|---|---|
| Aerial | Substrate | |||
| ISP2 | Good | Light pink to red | Orange-yellow to red | – |
| ISP3 | Good | Bright red | Red | – |
| ISP4 | Good | Pinky white | Pinky white | – |
| ISP5 | Good | Red in white | Red in white | – |
| ISP6 | Good | Transparent to pale violet red | Pale violet red | – |
| ISP7 | Good | Brick red | Vivid red | – |
| Gause’s No. 1 | Good | Vivid pink | Red | Claret-colored pigment |
–, absent
Fig. 1The scanning electron micrograph of Streptomyces sp. LRE541 cultured on the Gauze’s No. 1 medium for 2 weeks showing aerial mycelia and spores
Physiological properties of Streptomyces sp. LRE541
| Tests | Results | Tests | Results |
|---|---|---|---|
| Cellulose utilization | + | ||
| MR test | − | Urea | + |
| H2S production | − | Glycine | + |
| Peptone | + | ||
| Urease | + | Maizena | − |
| Catalase | + | Tyrosine | + |
| Starch hydrolysis | + | Aspartic acid | − |
| Gelatin hydrolysis | + | Soybean meal | + |
| Ammonium sulfate | + | ||
| Tween 20 | − | + | |
| Tween 40 | + | + | |
| Tween 80 | + | − | |
| Xylose | ++ | pH 2 | − |
| Starch | + | pH 4 | + |
| Glucose | ++ | pH 6 | + |
| Maltose | +++ | pH 7 | +++ |
| Lactose | +++ | pH 8 | ++ |
| Sucrose | ++ | pH 10 | ++ |
| Fructose | + | pH 12 | +++ |
| Mannose | ++ | ||
| Trehalose | − | 4–16 °C | − |
| Raffinose | − | 18–20 °C | + |
| Arabinose | + | 23 °C | +++ |
| Rhamnose | + | 28 °C | ++ |
| 37 °C | + | ||
| 0–6% | ++ | + | |
“−”, negative test; “+”, positive test/slight growth; “++”, well-growth; “+++”, very well growth
Fig. 2Maximum Likelihood tree exhibiting phylogenetic relationship between isolate LRE541 and the closely related representatives of Streptomyces spp. Only bootstrap values above 50% are present at the tree nodes. The scale bar denotes 0.01 substitutions per site
IC50 values of the LRE541 extract against various cell lines (μg/mL)
| Cell types | IC50 |
|---|---|
| Human colon cell RKO | 0.02127 |
| Human gastric adenocarcinoma 7901 | 0.2904 |
| Human liver carcinoma cell HepG2 | 1.484 |
| Human tongue cancer cell CAL-27 | 4.861 |
| Human breast carcinoma cell MCF-7 | 6.986 |
| Human chronic promyelocytic leukemia cell K562 | 8.106 |
| Human cervical cancer cell Hela | 10.87 |
| Human pancreatic cancer cell SW1190 | 12.98 |
| Human non-small cell lung cancer A549 | 16.94 |
| Human pulmonary artery endothelial cell HPAEC (human normal cell) | 20.14 |
Fig. 3Sensitivity of various types of cell lines (7901, RKO and HPAEC) to the LRE541 extract. The three cell lines were incubated with increasing concentrations of the LRE541 extract for 48 h, and their viabilities were determined by the MTT method. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the HPAEC cell line
Fig. 4The LRE541 extract induces apoptosis in RKO and 7901 cell lines. a The apoptotic cells change in RKO and 7901 cell lines when treated with increasing concentrations of the LRE541 extract for 48 h by Annexin V and PI double-staining assay. b The quantification of necrotic cells, apoptotic cells and normal cells. The data are presented as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control groups. c Early and late apoptotic cells of 7901 and RKO treated with varying concentrations of the LRE541 extract for 48 h
Fig. 5Effects of the LRE541 extract on cell cycles of RKO and 7901. a Cell cycle progressions of 7901 and RKO when treated with increasing concentrations of the LRE541 extract for 48 h. b Quantification of living cells distributing in three distinct phases of the cell cycle (G0/G1, S, and G2/M phase). The data are shown as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control groups
Fig. 6a, b Isolation and purification of 4-deoxy-ε-pyrromycinone at 11.263 min and epsilon-pyrromycinone at 8.965 min, respectively, by semi-HPLC; c chemical structures of the three pure compounds
13C NMR spectroscopic data of compounds (1)–(3) [400 MHz,δ (ppm)] purified from the LRE541extract
| (1) (CDCl3) | (2) (CDCl3) | (3) ((CD3)2CO) | |||
|---|---|---|---|---|---|
| Position | Position | Position | |||
| 1 | 159 | 1 | 158.6 | 2 | 144.8 |
| 2 | 130 | 2 | 130.3 | 3 | 104.4 |
| 3 | 129.7 | 3 | 129.8 | 3a | 126.6 |
| 4 | 157.9 | 4 | 158 | 4 | 119.7 |
| 5 | 191.2 | 5 | 191.1 | 5 | 120.7 |
| 6 | 161.8 | 6 | 161.2 | 6 | 127.3 |
| 7 | 20.3 | 7 | 62.6 | 7 | 110.7 |
| 8 | 28.8 | 8 | 32 | 7a | 136.2 |
| 9 | 71.8 | 9 | 70.1 | 8 | 112.4 |
| 10 | 57.3 | 10 | 57.6 | 9 | 122.2 |
| 11 | 121 | 11 | 120.8 | 10 | 160.3 |
| 12 | 186.5 | 12 | 185.3 | 12 | 52.2 |
| 13 | 171.7 | 13 | 170.3 | 13 | 166.9 |
| 14 | 53.4 | 14 | 53 | 15 | 40.1 |
| 15 | 32.6 | 15 | 34.7 | 15a × 2 | 27.9 |
| 16 | 7 | 16 | 6.3 | 16 | 146 |
| 4a | 113 | 4a | 112.5 | 17 | 112.3 |
| 5a | 131.3 | 5a | 132.2 | ||
| 6a | 134.5 | 6a | 132.8 | ||
| 10a | 142.1 | 10a | 142.6 | ||
| 11a | 114 | 11a | 114.9 | ||
| 12a | 112.9 | 12a | 112.3 | ||
IC50 values of the compounds 4-deoxy-ε-pyrromycinone (1), epsilon-pyrromycinone (2), and cisplatin (DDP) against various cancer cell lines (μg/mL). The data are shown as the mean ± SD of three independent experiments
| Compounds | A549 | HepG2 | SW1990 | RKO |
|---|---|---|---|---|
| (1) | 19.55 ± 5.2 | 20.42 ± 4.24 | 17.87 ± 2.73 | 14.96 ± 2.6 |
| (2) | 16.8 ± 0.75 | 18.6 ± 3.03 | 19.3 ± 4.32 | 12.9 ± 2.13 |
| DDP | 12.8 ± 0.37 | 13.3 ± 1.2 | 17.1 ± 2.8 | 16.72 ± 3.5 |